Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec 18;45(1):6.
doi: 10.1007/s10571-024-01515-z.

Application of Circulating Tumor DNA in the Auxiliary Diagnosis and Prognosis Prediction of Glioma

Ying Lu #  1 , Zhouyu Wang #  2 , Danmeng Zhang  1 , Ningning Luo  2 , Hui Yang  1 , Dongsheng Chen  3   4   5 , Haixin Huang  6
Affiliations
Review

Application of Circulating Tumor DNA in the Auxiliary Diagnosis and Prognosis Prediction of Glioma

Ying Lu et al. Cell Mol Neurobiol. .

Abstract

Glioma is the most common primary malignant brain tumor. Despite significant advances in the past decade in understanding the molecular pathogenesis of this tumor and exploring therapeutic strategies, the prognosis of patients with glioma remains poor. Accurate diagnosis of glioma is very important for the treatment and prognosis. Although the gold-standard method for the diagnosis and prognosis prediction of patients with glioma is tissue biopsy, it still has many limitations. Liquid biopsy can provide information on the auxiliary diagnosis and prognosis of gliomas. In this review, we summarized the application of cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) in the auxiliary diagnosis and prognosis of glioma. The common methods used to detect ctDNA in gliomas using samples including blood and cerebrospinal fluid (CSF) and the detection techniques for ctDNA, including droplet digital PCR (ddPCR) and next-generation sequencing (NGS), were discussed. Detection of ctDNA from plasma of patients with brain tumors remains challenging because of the blood-brain barrier (BBB). CSF has been proposed as a medium for ctDNA analysis in brain tumors, and mutation detection using plasma ctDNA was less sensitive than CSF ctDNA sequencing. Moreover, ongoing relevant clinical studies were summarized. Finally, we discussed the challenges, and future directions for the studies on ctDNA in glioma.

Keywords: Auxiliary diagnosis; CtDNA; Glioma; Next-generation sequencing; Prognosis.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of Interest: The authors declare no competing interests. Ethical Approval: Not applicable.

Figures

Fig. 1
Fig. 1
Application of ctDNA in gliomas (By Figdraw). ctDNA, circulating tumor DNA
Fig. 2
Fig. 2
Capabilities and shortcomings of cfDNA/ctDNA detection based on blood and CSF samples (By Figdraw). cfDNA, cell-free DNA. ctDNA, circulating tumor DNA. CSF, cerebrospinal fluid
See this image and copyright information in PMC

References

    1. Al Sharie S, Abu Laban D, Al-Hussaini M (2023) Decoding diffuse midline gliomas: a comprehensive review of pathogenesis, diagnosis and treatment. Cancers 15(19). 10.3390/cancers15194869 - PMC - PubMed
    1. Alpen K, Vajdic CM, MacInnis RJ, Milne RL, Koh ES, Hovey E, Harrup R, Bruinsma F, Nguyen TL, Li S, Joseph D, Benke G, Dugué PA, Southey MC, Giles GG, Rosenthal M, Drummond KJ, Nowak AK, Hopper JL, Kapuscinski M, Makalic E (2023) Australian genome-wide association study confirms higher female risk for adult glioma associated with variants in the region of CCDC26. Neuro Oncol 25(7):1355–1365. 10.1093/neuonc/noac279 - DOI - PMC - PubMed
    1. Anitha K, Posinasetty B, Naveen Kumari K, Chenchula S, Padmavathi R, Prakash S, Radhika C (2024) Liquid biopsy for precision diagnostics and therapeutics. Clin Chim Acta Int J Clin Chem 554:117746. 10.1016/j.cca.2023.117746 - PubMed
    1. Arvanitis CD, Ferraro GB, Jain RK (2020) The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nat Rev Cancer 20(1):26–41. 10.1038/s41568-019-0205-x - DOI - PMC - PubMed
    1. Bagley SJ, Nabavizadeh SA, Mays JJ, Till JE, Ware JB, Levy S, Sarchiapone W, Hussain J, Prior T, Guiry S, Christensen T, Yee SS, Nasrallah MP, Morrissette JJD, Binder ZA, O’Rourke DM, Cucchiara AJ, Brem S, Desai AS, Carpenter EL (2020) Clinical utility of plasma cell-free DNA in adult patients with newly diagnosed glioblastoma: a pilot prospective study. Clini Cancer Res Official J Am Assoc Cancer Res 26(2):397–407. 10.1158/1078-0432.Ccr-19-2533 - DOI - PMC - PubMed

LinkOut - more resources